

Vitaly Glozman

Manhattan Beach, Ca.

vitalyglozman@gmail.com

Summary

A senior consultant with expertise in strategy development, manufacturing scale-up, operational transformation, supply chain integration, and portfolio management in the Pharmaceutical and Public Health industries. As a lead Partner in the PwC's Pharma & Life Science and Global Health advisory practice, responsible for multi-national client management, and hands-on project delivery across strategy, operations, product development, and technology areas. Prior to PwC, a Partner (Director) with PRTM, a leading operations management consultancy, focusing on manufacturing operations and supply chain management. A published author in the areas of process and clinical development, manufacturing, and supply chain integration.

Experience

Partner, PwC, Pharma and Life Sciences Advisory (July 2011 – December 2022)

Los Angeles, California, United States

Global Health and NGO industry sector

- Established Vaccines Center of Excellence focusing on the development, manufacturing and commercialization of novel Vaccine platforms (mRNA, pDNA, viral vector)
- Supported scale-up of drug manufacturing operations from lab scale to commercial production
- Led consulting and programmatic engagements at the leading NGOs, including The Bill and Melinda Gates Foundation, Global Fund, and Children Investment Fund Foundation
- Supported CMC, manufacturing, and supply chain execution programs to reduce the burden of infectious diseases, particularly COVID-19, Malaria, Tuberculosis, HIV, and Polio
- Conducted grantee due diligence, and implemented governance and financial controls for partner networks
- Led programs to reduce manufacturing and distribution costs of diagnostics, vaccines, and small molecules

Pharmaceutical & Life Sciences management consulting practice

- Specialized in Manufacturing and Supply Chain for leading multi-national Pharma and Life Sciences companies (e.g., clinical and commercial supply, lean operations, capacity build-out, network expansion)
- Led strategy programs, focusing on operations, markets entry, advanced technologies, and partnerships
- Directed operational transformation, including R&D productivity and Supply Chain integration
- Established new consulting business focusing on Process Development and Tech Transfer advisory
- Created Digital Innovation practice that integrates tech. products and analytics tools into advisory services
- Published research on international regulatory environment and market entry

PRTM, Partner and Board of Directors Member (1999 – 2011)

Costa Mesa, California, United States

Health Industries consulting practice

- Led operations transformation practice for the pharmaceutical clients
- Specialized in Pharmaceutical acquisition integration, focusing on supply chain operations performance
- Established partnerships between Pharma companies and IDN providers to improve cost of delivery
- Developed Healthcare industry roadmap for deals strategies and financial implications (M&A, divestitures, PE, strategic partnerships)
- Led benchmarking services across supply chain, manufacturing, and quality competencies

PRTM (cont'd)

Board of Directors

- Expanded the US-based supply chain practice to address global network, particularly in Asia and Middle East
- Selected to Leadership Council responsible for policy development and services expansion for Health Industries sector
- Performed strategic and financial planning for long-term firm “big-bet” investment
- Led evaluation, development, and promotion processes for the consulting staff and Partners

Prior Experience:

- *Boeing Co.* – Huntington Beach, CA: Lead System Engineer and Program Head for C-17 program
- *Honeywell Allied Signal* – Torrance, CA: Avionics Engineer for classified Aerospace programs

Publications

- “*Disease X: accelerating the development of medical countermeasures for the next pandemic*”, March 2020 (The Lancet Infectious Disease, Shmona Simpson-The Bill & Melinda Gates Foundation and Vitaly Glozman-PwC) www.thelancet.com/action/
- “*Beyond the hype: Gene therapies require advanced capabilities to succeed after approval*”, September 2019 (PwC Health Research Institute, Vitaly Glozman, et al)
- “*Succeeding in pharma beyond 2020*”, June 2016 (Strategy& PwC, Vitaly Glozman, et al)
- “*Emerging markets growth: Leveraging operations to gain a competitive advantage*”, March 2013 (PwC Point of View publication, Vitaly Glozman, et al)
- “*Managing Clinical Trials in Global Markets through Hub-and-Spoke System*”, January 2011 (Pharmaceutical Executive, Romi Singh-Amgen and Vitaly Glozman-PwC / PRTM)

Education

Executive Program – Artificial Intelligence: Implications for Business Strategy (2017-2018)

Massachusetts Institute of Technology (MIT), Cambridge, MA

MBA – Finance and Operations (1991-1993)

University of Southern California (USC), Los Angeles, CA

Bachelor of Science – Mechanical Engineering (1985-1989)

California Polytechnic University, Pomona, CA